Abbott receives fda clearance for first commercially available lab-based blood test to help evaluate concussion

New test will run on abbott's alinity® i laboratory instrument, complementing abbott's rapid i-stat tbi plasma test, cleared by the fda in 2021 given the significant number of alinity i instruments in use in labs across the u.s., abbott's lab test will make concussion testing available to more people across the country test helps doctors evaluate patients with mild traumatic brain injury (mtbi), commonly known as concussion, by ruling out the need for a ct scan abbott park, ill., march 7, 2023 /prnewswire/ -- abbott (nyse: abt) has received u.s. food and drug administration clearance for what will be the first commercially available laboratory traumatic brain injury (tbi) blood test, making it widely available to hospitals in the united states.
ABT Ratings Summary
ABT Quant Ranking